EBAMED, SWISS-ITALIAN COMPANY, RAISES EUR 14.35 MILLION IN SERIES A FUNDING TO DEVELOP ITS NOVEL IMAGE GUIDANCE SYSTEM FOR THE NON-INVASIVE TREATEMENT OF VENTRICULAR TACHYCARDIA THROUGH PROTON THERAPY

GENEVA, June 27, 2023 –EBAMed SA, a Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias, announced today the raising of 14.35 M € in Series A Funding to accelerate the development of an innovative device to advance cardiac radiation ablation therapy. The financing round was led by Panakès Partners, a venture capital firm with headquarters in Milan, together with the EIC Fund, Swiss EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, and OCCIDENT. The round was also supported by existing investors, including Mayo Clinic.

The fund will be used to bring EBAMed’s CardioKit system – a device that automatically adjusts cardiac radiation ablation systems for cardiac motion and increases external beam delivery precision – up to the completion of its First in Human trials.
The development of a radiation therapy approach, combined with a unique motion monitoring and gating solution, will fill an important need for alternatives to either drug therapy or catheter-based ablation, and for reduced radiation of healthy myocardium.

EBAMED ANNOUNCES FIRST PATIENT ENROLLED IN PROSPECTIVE IMAGING STUDY WITH ULTRASOUND GUIDANCE PROTOTYPE IN VENTRICULAR TACHYCARDIA PATIENTS

PAVIA, July 16, 2021 –EBAMed SA, an early-stage medical device company pioneering new approaches to proton therapy today announced the enrollment of the first patient in a prospective imaging study using a device that automatically interprets cardiac ultrasound images to uniquely track the motion of the heart.

The first patient was enrolled at the Policlinico San Matteo, Pavia (Italy). This important company milestone was reached according to development schedule.

The main objectives of the study are to collect cardiac ultrasound data from patients diagnosed with ventricular tachycardia (VT). The investigators will analyze ultrasound image data quality and establish if it is adequate to support the development of an add-on medical device to guide proton-therapy systems currently used in oncology and adapt the technology to non-invasive treatment of cardiac arrhythmias. Such device would also include a gating signal generator to precisely gate treatment beams, which are delivered to the patients during radio-ablation procedures.

WE ARE PRESENT THIS YEAR AT #AAPM2021AnnualMeeting with news about Ultrasound Image Guidance for Interventions. https://lnkd.in/eN8Xt7H

GENEVA, June 1 2021

INTERVIEW WITH EXPERTS: MARINA IZZO, CEO

GENEVA, March 18 2021 –Venture asked Marina Izzo about her experiences in the industry and her vision for EBAMed.

You can find the complete article at: https://lnkd.in/dMuseyw

SWISS-BASED MEDTECH STARTUP EBAMED APPOINTS MARINA IZZO AS CEO

GENEVA, February 18 2021 –EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as Chief Executive Officer (CEO). Mrs. Izzo will set the vision for EBAMed’s technology and lead the effort for the next financing round, planned for 2022. Former CEO and co-founder, Adriano Garonna has transitioned to Chief Technology Officer (CTO) and maintains a role on the company’s Board of Directors. 

EBAMED IS AWARDED EUR 2.4 MILLION BY THE EUROPEAN UNION TO DEVELOP ITS CARDIAC MOTION MANAGEMENT PRODUCT FOR THE NON-INVASIVE TREATMENT OF HEART ARRHYTHMIAS

GENEVA, September 23, 2020 – EBAMed SA has been awarded EUR 2.4 million in a non-dilutive grant (agreement No. 954783) by the Enhanced European Innovation Council (EIC) to develop its cardiac motion management product for the non-invasive treatment of heart arrhythmias. The grant enables EBAMed to optimize the product’s hardware and software components

“The procedure is quick, safe, painless and suitable for any age and health condition patient with no side effects and we expect it will provide an efficient alternative to existing treatments,” states EBAMed’s co-founder, Prof. Ugo Amaldi (CERN). “EBAMed will work with several clinical institutions, such as the National Center of Oncological Hadron therapy CNAO in Italy and the University Hospital UZ Leuven in Belgium, in order to fine-tune the use of its technology.”

The Horizon2020 EIC pilot aims to support top-class innovators, start-ups, small companies and researchers with bright ideas that are radically different from existing products, services or business models, are highly risky and have the potential to scale up internationally. 

EBAMED JOINS THE MAYO CLINIC BUSINESS ACCELERATOR AND STARTS PRE CLINICAL TESTING

GENEVA, Switzerland, March 10, 2020 – _EBAMed SA is glad to announce its entry into the Mayo Clinic Business Accelerator located in Rochester, Minnesota, USA, in January 2020. This will allow EBAMed to work closely with Mayo Clinic on pre-clinical tests whilst ensuring a first presence in the United States.

EBAMED CLOSES CHF 1.2 MILLION SEED FINANCING TO ADVANCE NON-INVASIVE THERAPY FOR HEART ARRHYTHMIAS. FUNDING SUPPORTS DEVELOPMENT OF FIRST INTEGRATED HEART MOTION MANAGEMENT SYSTEM AND PRE-CLINICAL TESTING

GENEVA, August 21, 2019